AI Article Synopsis
- There have been significant advancements in ocular oncology for diagnosing and treating tumors in the eye and surrounding areas, with a focus on targeted therapies.
- Targeted therapies use drugs that specifically target genetic mutations and pathways in tumor cells, reducing damage to normal cells compared to traditional chemotherapy.
- Current research and clinical trials show promising results for targeted therapies in treating various eye-related tumors, leading to improved survival rates and better patient tolerance.
Article Abstract
There have been rapid advancements in the field of ocular oncology for the diagnosis and management of intraocular, adnexal, and orbital tumors. Targeted therapy is in the forefront of medical research in all fields including ocular oncology. Targeted therapy include drugs that target specific genetic mutations, pathways or proteins involved in the development of cancer. In contrast to traditionally used chemotherapy, drugs used in targeted therapy are highly specific for tumor cells and preserve the function of normal cells. This review aims to familiarize ophthalmologists with the drugs that are currently approved or undergoing clinical trials for use in ocular oncology. Targeted therapy is particularly useful for locally advanced or metastatic tumors, including but not limited to eyelid and periocular basal cell carcinoma, periocular cutaneous and conjunctival squamous cell carcinoma, ocular adnexal lymphoma, conjunctival melanoma, and uveal melanoma. The results are promising with improved survival outcomes and better tolerability than chemotherapeutic drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apjo.2024.100062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!